ChiCTR2600119185 版本V1.0 版本创建时间2026/02/24 11:11:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119185 

最近更新日期:

Date of Last Refreshed on:

2026-02-24 11:11:29 

注册时间:

Date of Registration:

2026-02-24 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

虚拟现实技术(Virtual Reality,VR)联合静脉自控镇痛用于儿童术后镇痛的临床研究

Public title:

Application of Virtual Reality (VR) combined with patient controlled intravenous analgesia in Postoperative Pain Management in Pediatric Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

虚拟现实技术(Virtual Reality,VR)联合静脉自控镇痛用于儿童术后镇痛的临床研究

Scientific title:

Application of Virtual Reality (VR) combined with patient controlled intravenous analgesia in Postoperative Pain Management in Pediatric Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李赛男 

研究负责人:

魏灵欣 

Applicant:

Li Sainan 

Study leader:

Wei Lingxin 

申请注册联系人电话:

Applicant telephone:

+86 158 0120 7152

研究负责人电话:

Study leader's
telephone:

+86 155 2200 2357

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1754177403@qq.com

研究负责人电子邮件:

Study leader's E-mail:

weilx3934@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市石景山区八大处路33号

研究负责人通讯地址:

北京市石景山区八大处路33号

Applicant address:

No.33 Badachu Road, Shijingshan District, Beijing

Study leader's address:

No.33 Badachu Road, Shijingshan District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医学科学院整形外科医院

Applicant's institution:

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

研究负责人所在单位:

中国医学科学院整形外科医院

Affiliation of the Leader:

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)注册第(140)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医学科学院整形外科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Plastic Surgery Hospital, Chinese Academy of Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2024-03-25 00:00:00

伦理委员会联系人:

裴晔

Contact Name of the ethic committee:

Pei Ye

伦理委员会联系地址:

北京市石景山区八大处路33号

Contact Address of the ethic committee:

No.33 Badachu Road, Shijingshan District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 5396 8034

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医学科学院整形外科医院

Primary sponsor:

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

研究实施负责(组长)单位地址:

北京市石景山区八大处路33号

Primary sponsor's address:

No.33 Badachu Road, Shijingshan District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国医学科学院整形外科医院

具体地址:

北京市石景山区八大处路33号

Institution
hospital:

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

Address:

No.33 Badachu Road, Shijingshan District, Beijing

经费或物资来源:

自筹经费

Source(s) of funding:

Self-raised

研究疾病:

无  

Target disease:

None

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

主要目的:探索虚拟现实技术(Virtual Reality,VR)联合静脉自控镇痛泵用于儿童术后镇痛的临床效果。 次要目的: 1.评估儿童围术期应用VR对健康是否有益; 2.评估VR技术辅助在减少术后疼痛方面的有效性; 3.比较VR辅助下的镇痛管理与传统PCA治疗在提升患儿术后满意度方面的差异; 4.分析VR技术在减少阿片类药物使用及其副作用方面的潜力; 5.探讨不同年龄段儿童对VR镇痛管理的接受度和反应; 6.评估VR降低术前手术室内的焦虑程度,提高麻醉诱导配合程度; 7.评估VR缓解进入手术室后静脉穿刺置管时疼痛程度;  

Objectives of Study:

Primary Objective: To explore the clinical effects of virtual reality (VR) combined with intravenous patient-controlled analgesia (PCA) pumps for postoperative pain management in children. Secondary Objectives: 1. To assess whether the use of VR during the perioperative period benefits children's health; 2. To evaluate the effectiveness of VR-assisted technology in reducing postoperative pain; 3. To compare VR-assisted pain management with traditional PCA in improving postoperative satisfaction in children; 4. To analyze the potential of VR technology in reducing the use of opioids and their side effects; 5. To investigate the acceptance and response to VR pain management among children of different age groups; 6. To assess whether VR can reduce preoperative anxiety in the operating room and improve cooperation during anesthesia induction; 7. To evaluate the effectiveness of VR in alleviating pain during intravenous cannulation after entering the operating room.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

择期手术需术后镇痛治疗的5-10岁儿童。

Inclusion criteria

Children aged 5-10 who require postoperative analgesia for elective surgery.

排除标准:

a.癫痫发作、晕动病史 b.认知或学习障碍 c.感觉障碍 d.拒绝签署知情同意书 e.幽闭恐惧症

Exclusion criteria:

1. Epileptic seizure history, history of motion sickness; 2. cognitive dysfunction or inability to learn; 3. Sensory disorder; 4. Refused to sign the informed consent; 5. Claustrophobia.

研究实施时间:

Study execute time:

From 2024-06-01 00:00:00 To 2026-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-21 00:00:00 To 2024-08-30 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

63

Group:

A group

Sample size:

干预措施:

VR+舒芬太尼0.05ug/kg/h PCIA, VR+标准治疗下建立静脉输液通路

干预措施代码:

Intervention:

VR+Sufentanil 0.05ug/kg/h PCIA,establishing intravenous infusion access under VR+ standard treatment

Intervention code:

组别:

B组

样本量:

63

Group:

B group

Sample size:

干预措施:

舒芬太尼0.05ug/kg/h PCIA,标准治疗下建立静脉通路

干预措施代码:

Intervention:

Sufentanil 0.05ug/kg/h PCIA, establishing intravenous infusion access under standard treatment

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

石景山 

Country:

China

Province:

Beijing

City:

Shijingshan

单位(医院):

中国医学科学院整形外科医院 

单位级别:

三甲 

Institution
hospital:

Plastic Surgery Hospital, Chinese Academy of Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后1h、6h、12h、24h评估干预前、干预后立即的Wong-Baker评分

指标类型:

主要指标

Outcome:

Wong-Baker FACES Pain Rating Scale scores evaluated pre-intervention and immediately post-intervention at 1, 6, 12, and 24 hours after surgery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术室等候区儿童mYPAS评分

指标类型:

次要指标

Outcome:

Children’s mYPAS scores in the preoperative holding area

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PCIA使用记录

指标类型:

次要指标

Outcome:

PCIA usage records

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术室后干预前、干预后CPMAS评分

指标类型:

次要指标

Outcome:

CPMAS scores assessed before and after the intervention in the post–operating room setting

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

进入手术室后干预前、干预后心率

指标类型:

次要指标

Outcome:

Heart rate measured before and after the intervention after entering the operating room

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

进入手术室后干预前、干预后血压

指标类型:

次要指标

Outcome:

Blood pressure measured before and after the intervention after entering the operating room

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

进入手术室后干预前、干预后血氧饱和度

指标类型:

次要指标

Outcome:

SpO2 assessed pre- and post-intervention following admission to the operating room"

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

麻醉诱导期合作度

指标类型:

次要指标

Outcome:

induction compliance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1h、6h、12h、24h评估干预前、干预后立即的FLACC评分

指标类型:

次要指标

Outcome:

FLACC scores assessed pre- and immediately post-intervention at 1, 6, 12, and 24 hours after surgery.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

进行静脉穿刺置管时Wong- Baker评分

指标类型:

次要指标

Outcome:

Wong-Baker FACES Pain Rating Scale score assessed during intravenous catheterization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

进行静脉穿刺置管时FLACC量表评分

指标类型:

次要指标

Outcome:

FLACC scale score assessed during intravenous catheterization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇痛药物使用的种类、时间和剂量

指标类型:

次要指标

Outcome:

The types, timing and dosage of analgesic drugs used

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1h、6h、12h、24h评估干预前、干预后心率

指标类型:

次要指标

Outcome:

Heart rate was measured pre- and immediately post-intervention at 1, 6, 12, and 24 hours after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1h、6h、12h、24h评估干预前、干预后血压

指标类型:

次要指标

Outcome:

Blood pressure was measured pre- and immediately post-intervention at 1, 6, 12, and 24 hours after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后1h、6h、12h、24h评估干预前、干预后血氧饱和度

指标类型:

次要指标

Outcome:

SpO2 was measured pre- and immediately post-intervention at 1, 6, 12, and 24 hours after surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 5 years
最大 Max age 10 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

计算机生成的随机化数字表。

Randomization Procedure (please state who generates the random number sequence and by what method):

A computer-generated randomized digital table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本研究在患者进入手术室佩戴VR设备前是不知情的,由于VR设备的使用,因此使用VR设备后属于开放性试验。

Blinding:

In this study, patients were blinded prior to entering the operating room and wearing the VR device. However, due to the nature of VR use, the intervention was considered an open-label trial after the device was applied.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文发表后半年内,国家人口健康科学数据中心,https://www.ncmi.cn/index.html

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the paper is published,National Population Health Science Data Center, https://www.ncmi.cn/index.html

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用CRF病例记录表和EXCEL表格收集和管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data were collected and managed by using CRF and EXCEL

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-24 11:11:29